<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109587</url>
  </required_header>
  <id_info>
    <org_study_id>Probiotics/Diabetes Prevention</org_study_id>
    <nct_id>NCT03109587</nct_id>
  </id_info>
  <brief_title>Pilot Study of Probiotics in Pre-diabetic Adolescents</brief_title>
  <acronym>ProDP</acronym>
  <official_title>Pilot Study of Probiotics in Pre-diabetic Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the feasibility and effect of probiotics on glycemic control in obese
      adolescents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diet-induced intestinal dysbiosis in obese children contributes to the development of type 2
      diabetes mellitus (T2D). Probiotic treatment has been proposed to alleviate glycemic
      dysfunction and prevent/delay development of T2D. The investigators will test probiotics to
      improve insulin sensitivity and preserve beta cell function in obese children.

      The probiotic strains are known to improve glycemic control.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The study product will be prepackaged and will be supplied and labeled only with the Protocol Number.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in microbiota composition</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Microbiome (16S rRNA) analysis, fecal immunoglobulin (Ig)A</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in insulin resistance</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Measures of homeostatic model assessment of insulin resistance (HOMA-IR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation in blood</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>measures of high sensitive cardio-reactive protein (hsCRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation in the gut</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>measure of fecal calprotectin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Obesity, Childhood</condition>
  <arm_group>
    <arm_group_label>Vivomixx (Visbiome)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 packets of probiotics by mouth/day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>identical in appearance, but without probiotics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vivomixx</intervention_name>
    <description>900 billion of the following probiotic strains: L. acidophilus DSM24735; L. plantarum DSM24730; L. paracasei DSM24733; L. delbrueckii supsp. bulgaricus DSM24734, S. thermophilus DSM24731, B. longum DSM24736, B. breve DSM24732, and B. infantis DSM24737) maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)</description>
    <arm_group_label>Vivomixx (Visbiome)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 13-19 y. of age at Visit 1.

          -  BMI: 99th percentile or greater

          -  Acanthosis nigricans

          -  Pubertal Tanner stage â‰¥3

        Exclusion Criteria:

          -  Secondary diabetes (i.e. post-transplant diabetes mellitus (DM) or cystic fibrosis
             DM), monogenic forms of diabetes (i.e. MODY), autoimmune diabetes or presence of islet
             autoantibodies.

          -  Known severe immunodeficiency, or immune compromised.

          -  Current or previous history for insulin or metformin therapy (within last 3 months).

          -  Antibiotic or probiotic therapy 3 months prior to enrollment.

          -  Start of new dietary intervention within 1 month prior to enrollment.

          -  Diagnosed food hypersensitivity or active gastrointestinal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian L Roth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christiane S Hampe, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian L Roth, MD</last_name>
    <phone>206 987 5428</phone>
    <email>christian.roth@seattlechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Kearns, RN, MN</last_name>
    <phone>206 987-1758</phone>
    <email>Sue.kearns@seattlechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seattle Children's Hosptital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Kearns, RN</last_name>
      <phone>206-987-1758</phone>
      <email>sue.kearns@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Christian Roth</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arushi Verma</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Christian Roth</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pediatric Obesity</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

